Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

EGFR inhibitors have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Mefatinib is a novel, bioavailable, second-generation, irreversible pan- EGFR inhibitor. This phase Ib/II open-label, single-arm, multi-center study investigated the efficacy, safety, biomarker, and res...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Signal transduction and targeted therapy 2021-11, Vol.6 (1), p.374-9, Article 374
Hauptverfasser:	Wang, Pingli, Li, Yuping, Lv, Dongqing, Yang, Lingge, Ding, Liren, Zhou, Jianya, Hong, Wei, Chen, Youfei, Zhang, Dongqing, He, Susu, Zhou, Jianying, Wang, Kai
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/68 631/67/1612 Adult Adverse events Aged Amino Acid Substitution Biochemistry & Molecular Biology Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - secondary Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Biology Disease control Epidermal growth factor receptors ErbB Receptors - genetics ErbB Receptors - metabolism Female Humans Internal Medicine Life Sciences & Biomedicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Male Medicine Medicine & Public Health Metastases Middle Aged Mutants Mutation Mutation, Missense Neoplasm Metastasis Non-small cell lung carcinoma Oncology p53 Protein Pathology Patients Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Science & Technology Small cell lung carcinoma Toxicity Tumor Suppressor Protein p53 - genetics Tumor Suppressor Protein p53 - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!